Medical Oncology 1 – Medical Oncology Unit: Melanoma
Milano
Via Giacomo Venezian, 1 , 20133 Milano MI
The Melanoma Unit at the IRCCS National Cancer Institute Foundation in Milan is a unit dedicated to the diagnosis, treatment and clinical-translational research of cutaneous, mucosal and uveal melanoma, in both early and advanced stages. The unit offers a personalised treatment pathway, based on innovative and integrated therapeutic approaches, through highly specialised, research-oriented multidisciplinary management, with the possibility of access to experimental drugs within the context of Phase I-II-III clinical trials.
The clinical organisation includes:
- Weekly outpatient clinics for initial oncology consultations, dedicated to the intake of new patients;
- Oncology follow-up clinics, for the monitoring of patients undergoing active treatment or follow-up;
- Daily clinics for the administration of oral and infusion therapies, both standard and experimental, within the framework of active clinical protocols;
The Melanoma Unit is an active part of the multidisciplinary Melanoma & Skin Cancer and Metastatic Uveal Melanoma (MUM) group, which coordinates:
- Multidisciplinary team meetings for patients already diagnosed who require a multimodal treatment strategy (surgery, radiotherapy, oncology, interventional radiology).
An active component of the unit is clinical and translational research through the conduct of national and international clinical trials
To book an initial melanoma consultation under the National Health Service (NHS), you can contact the CUP (Central Booking Office) on 0223901 or book directly at the reception desks of the IRCCS National Cancer Institute Foundation.
Initial oncology consultations are held on the following days and at the following times:
- Tuesday and Wednesday afternoons from 2.00 pm to 4.00 pm
Melanoma oncology consultations are guaranteed promptly through the NHS (generally within 15 days).
For those who wish, the option of a private consultation is also available.
Patients are advised to bring all available clinical documentation to the consultation (radiology reports, histological examinations, blood tests, previous specialist assessments) to allow for a comprehensive assessment of the case.
- Mail: segreteria.oncologiamedica@istitutotumori.mi.it
- Mail: segreteria.om1@istitutotumori.mi.it
- Tel: 0223903066
- Tel: 0223903650
Dal lunedì al venerdì dalle 9.00 alle 17.00.
Orari di accesso informatori scientifici: su appuntamento
Dott. Del Vecchio Michele
Head
Dott.ssa Indini Alice
Medical Director
Dott.ssa Di Guardo Lorenza
Senior Staff Physician
Dott. Spagnoletti Andrea
Medical Director
Dr.ssa Cecilia Silvestri Specializzanda
Dott. Alessio Arata – Infermiere di Ricerca Senior
Dr.ssa Vittoria Bungaro – Infermiere di Ricerca
Dr.ssa Ilaria Bisogno Data Manager Senior
Dr.ssa Maria Montesanto Data Manager
Dr.ssa Luana Docimo Data Manager
Dr.ssa Valentina Nieddu Data Manager
Dr.ssa Maria Fruci Data Manager
A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator- Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (I
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*0201 positive patients with high-risk non-metastatic uveal melanoma: an EORTC randomized phase III study (ATOM Trial)
IDE196 (DAROVASERTIB) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma (DAR-UM-2)
Cancer Cell-Intrinsic PD-1 and immune-microenvironment boost tumor growth upon immune-checkpoint inhibitors in NSCLC
Last update: 23/04/2026